“To build a biotech you need to be addicted to passion and addicted to doing the right thing for patients,”
Re-Vana Therapeutics’ have opened anew laboratory and office facility at the Catalyst Innovation Centre in Belfast’s Titanic Quarter.
Re-Vana Therapeutics is a biotechnology company founded in 2016 as a spin-out from Queen’s University Belfast who focus on the development of long-acting drug delivery technologies for severe retinal blinding diseases, with the aim of reducing treatment burden and improving patient outcomes.
Following a period of significant growth, Re-Vana has recently relocated from its original 3,000 sq. ft. premises in QUB to a new 8,000 sq. ft. purpose-built laboratory and office space at Catalyst.
The reception brought together members of the Re-Vana team, government representatives, investors, academic collaborators, and colleagues from across the life sciences ecosystem and provided an informal opportunity to view the new facilities and to celebrate an important step in Re-Vana’s continued development and the companys advancing pipeline, and long-term commitment to building a globally competitive life sciences company in Northern Ireland.
CEO Michael J. O’Rourke, opening the event said, “Such a fantastic facility for ocular sustained release drug delivery research and development which will provide better treatments for patients. I’m looking forward to seeing growth, meeting new staff, building our product pipeline and deepening our relationship with Boehringer Ingelheim. To build a biotech you need to be addicted to passion and addicted to doing the right thing for patients we are excited for this next wave.”
HIRANI CEO, Joann Rhodes MBA, welcoming the new facility, said: “It is really inspiring to see the new Revana Therapeutics laboratories putting biotech research and development on the map in Belfast.”
